CLINICAL TRIALS PROFILE FOR RELYVRIO
✉ Email this page to a colleague
All Clinical Trials for RELYVRIO
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT05619783 ↗ | Extension Study Evaluating The Safety And Tolerability of AMX0035 | Not yet recruiting | Amylyx Pharmaceuticals Inc. | Phase 3 | 2022-11-01 | The primary objective is to evaluate the safety and tolerability of AMX0035 over 108 weeks of open label treatment for participants previously enrolled in Study A35-004 (PHOENIX). |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for RELYVRIO
Condition Name
Clinical Trial Locations for RELYVRIO
Clinical Trial Progress for RELYVRIO
Clinical Trial Phase
Clinical Trial Sponsors for RELYVRIO
Sponsor Name